Pyrazine derivatives and pharmaceutical use thereof

Details Pyrazine derivatives and pharmaceutical use thereof Pyrazine derivatives and pharmaceutical use thereof

2004-10-26

2008-08-05

Tucker, Zachary C (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S405000

Reexamination Certificate

active

07407961

ABSTRACT:
A pyrazine derivative of the following formula (I):or a salt thereof.The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.

REFERENCES:
patent: 6673802 (2004-01-01), Castelhano et al.
patent: 6995161 (2006-02-01), Yoon et al.
Parry et al, “Functionalized Pyridylboronic Acids and Their Suzuki Cross-Coupling Reactions to Yield Novel Heteorarylpyridines” Journal Organic Chemistry, vol. 67, pp. 7541-7543 (2002).
Popoli et al, “Adenosine A2a Receptor Antagonism and Neuroprotection: Mechanisms, Lights, and Shadows” Critical Reviews in Neurobiology, vol. 16(1&2), pp. 99-106 (2004).
Fredholm and Svenningsson, “Adenosine-dopamine interactions: Development of a concept and some comments on therapeutic possibilities” Neurology, vol. 61 (Suppl. 6), pp. S5-S9 (2003).
Maemoto et al, “Pharmacological Characterization of FR194921, a New, Potent, Selective, and Orally Active Antagonist for Central Adenosine A1 Receptors” Journal of Pharmacological Science, vol. 96, pp. 42-52 (2004).
Pitsikas and Borsini, “The Adenosine A1 Receptor Antagonist BIIP 20 Counteracts Scopolamine-Induced Behavioral Deficits in the Passive Avoidance Task in the Rat” European Journal of Pharmacology, vol. 328, pp. 19-22 (1997).
Yacoubi et al, “Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A knockout mice.” British Journal of Pharmacology, vol. 134, pp. 68-77 (2001).
Chen et al, “A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice” The Journal of Neuroscience, vol. 19(21), pp. 9192-9200 (1999).
Monopoli et al, “Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats” Neuroreport, vol. 9, pp. 3955-3959 (1998).
Ledent et al, “Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor” Nature, vol. 388, pp. 674-678 (2004).

Affiliated with

Also associated with

Rating

Pyrazine derivatives and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazine derivatives and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazine derivatives and pharmaceutical use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013450